UAE Diabetes Care Devices Market Overview, 2031

Key Insights

• According to the research report, "UAE Diabetes Care Devices Market Outlook, 2031," published by Bonafide Research, the UAE Diabetes Care Devices Market is anticipated to grow at more than 12.35% CAGR from 2026 to 2031.
• The UAE diabetes care devices market operates within a highly sophisticated, mandatory insurance ecosystem overseen by regional health authorities like the Department of Health - Abu Dhabi (DoH) and the Dubai Health Authority (DHA). Comprehensive insurance frameworks such as the Thiqa plan in Abu Dhabi and enhanced basic benefit packages in Dubai provide mandatory public coverage for continuous glucose monitoring (CGM) systems, automated insulin pumps, and associated disposables for citizens and expatriates with Type 1 diabetes and intensive insulin-treated Type 2 diabetes. Strategic breakthroughs in the UAE market center on Ministry of Health and Prevention (MOHAP) fast-track approvals for factory-calibrated 14-day continuous sensors (such as the Dexcom G7 and Abbott FreeStyle Libre 3) and advanced hybrid closed-loop systems (e.g., Medtronic MiniMed 780G and Omnipod 5).
• The UAE stands out globally for its rapid integration of wearable diabetes hardware into government-backed digital health ecosystems. Driven by national AI strategies and smart government mandates, medical technology providers are pairing continuous glucose monitors and smart insulin pen accessories directly with regional healthcare platforms such as Malaffi in Abu Dhabi and Nabidh in Dubai. A major technological breakthrough is the automated synchronization of Ambulatory Glucose Profile (AGP) data from home-use wearables directly into central electronic medical record (EMR) portals.
• Data from the International Diabetes Federation (IDF) and regional health studies indicate that the UAE faces one of the highest diabetes prevalence rates in the world, with approximately 20.7% of the adult population (aged 20–79) representing over 1.27 million adults living with diabetes. Furthermore, an estimated 300,000 adults in the UAE remain formally undiagnosed, while over 1.2 million individuals present with prediabetes or impaired glucose tolerance. Type 1 diabetes affects tens of thousands of residents across the Emirates, with a high regional incidence among pediatric and young adult populations. From an economic perspective, direct annual diabetes-related health expenditure in the UAE exceeds $1.6 billion USD, with average per-person healthcare spending for diabetes management reaching over $2,100 USD annually.

Market Outlook

• Major e-pharmacy platforms and retail pharmacy chains (such as Aster Pharmacy, Life Pharmacy, and BinSina Pharmacy) serve as primary access points where consumers purchase over-the-counter biosensors, smart insulin pen accessories, and continuous monitoring kits. As regulatory pathways expand for non-prescription over-the-counter biosensors, device manufacturers are targeting non-insulin Type 2 diabetics, prediabetic cohorts, and health-conscious consumers seeking real-time metabolic insights, shifting device positioning from reactive diagnostic hardware toward proactive lifestyle management.
• Medical device registration, safety compliance, and rapid import authorizations are overseen nationally by the Ministry of Health and Prevention (MOHAP), while local healthcare delivery and insurance coding are governed by the Department of Health - Abu Dhabi (DoH) and the Dubai Health Authority (DHA). Clinical protocols, research initiatives, and professional practice standards are led by prominent professional and advocacy bodies, including the Emirates Diabetes and Endocrine Society (EDES) and the Emirates Medical Association (EMA). Prominent commercial companies leading the UAE market include Abbott Laboratories Middle East, Dexcom, Medtronic Meta, Roche Diabetes Care Middle East, Ascensia Diabetes Care, Insulet Corporation, Ypsomed, and Sanofi Middle East.

Market Dynamics

Driver: Mandatory health insurance mandates and high-coverage public benefit packages
The primary growth driver for the UAE diabetes care devices market is the robust, government-enforced mandatory health insurance framework enacted across the Emirates, most notably by the Department of Health – Abu Dhabi (DoH) and the Dubai Health Authority (DHA). Under regulatory frameworks like Abu Dhabi’s Thiqa scheme for UAE nationals and enhanced basic benefit packages for expatriate residents, coverage for Continuous Glucose Monitoring (CGM) systems, automated insulin pumps, and associated infusion supplies is legally mandated for individuals diagnosed with Type 1 diabetes and intensive insulin-treated Type 2 diabetes.
Challenge: High expatriate population turnover, formularies disparities, and reimbursement delays
Despite comprehensive healthcare mandates, market expansion in the UAE faces unique operational hurdles stemming from high demographic mobility within the expatriate workforce, insurance tiering disparities, and administrative reimbursement delays. Expatriates make up over 85% of the UAE's total population, and their health insurance coverage is tied to employer-sponsored benefit plans that vary widely in tiering, prescription co-pays, and medical device formularies.
Trend: Integration into unified digital health portals (Malaffi/Nabidh) and preventive biosensing
A defining trend reshaping the UAE’s diabetes care market is the integration of cloud-connected wearable device data directly into centralized government digital health platforms, paired with the rise of over-the-counter (OTC) metabolic biosensing. Under the UAE’s national digital transformation and AI strategy, continuous glucose monitors, smart insulin pens, and connected pumps automatically sync Ambulatory Glucose Profile (AGP) and Time-in-Range (TIR) metrics into unified health information exchanges such as Abu Dhabi’s Malaffi and Dubai’s Nabidh platforms.

Segment Analysis

UAE Diabetes Care Devices By Product Type
• The UAE’s blood glucose monitoring systems market combines traditional finger-prick meters with continuous glucose monitoring (CGM) and connected digital health solutions. A distinctive market characteristic is the growing integration of glucose information with smartphone applications and specialist diabetes services, allowing patients to review glucose trends alongside meals, physical activity, and medication routines. The country’s hot climate also makes sensor adhesion, skin comfort, and reliable device performance during outdoor activities particularly relevant product considerations. Manufacturers can differentiate themselves through Arabic- and English-language interfaces, clear glucose reports, accessible technical support, and seamless data sharing with clinicians.
• The UAE’s insulin delivery devices market includes insulin pens, syringes, insulin pumps, and automated insulin delivery systems. Insulin pens remain relevant for their convenience and straightforward administration, while connected pens and pump technologies offer opportunities for more individualized treatment management. Integration between insulin pumps and CGM systems is an important differentiator because it can help users and clinicians coordinate glucose monitoring and insulin delivery.



UAE Diabetes Care Devices By Disease Type
• The UAE’s type 1 diabetes segment is characterized by the need for continuous glucose assessment, reliable insulin administration, and individualized treatment support. CGM systems, insulin pumps, and automated insulin delivery technologies are particularly relevant because they can help users respond to glucose fluctuations and manage intensive insulin therapy. Specialist diabetes centers provide an important environment for device selection, clinical education, and ongoing treatment adjustments. A distinctive opportunity lies in integrated systems that allow patients, caregivers, and clinicians to review glucose trends through connected platforms.
• The UAE’s type 2 diabetes segment requires a varied range of monitoring solutions because patients may manage the condition through lifestyle changes and oral medication or require insulin therapy. Conventional glucose meters remain useful for targeted testing, while CGM can provide a more detailed view of glucose responses to meals, exercise, and medication for appropriately selected patients. The market offers opportunities for digital monitoring solutions that connect personal glucose information with clinical consultations and personalized lifestyle guidance. However, device selection must reflect clinical requirements, ease of use, and the patient's ability to sustain ongoing use.

UAE Diabetes Care Devices By End User
• The UAE’s home and self-care segment is supported by the availability of connected monitoring devices, wearable sensors, insulin pens, and digital health applications. Patients can use these technologies to monitor glucose between appointments and share relevant information with healthcare professionals. The country’s multilingual population creates a need for interfaces and educational resources that accommodate different language preferences and levels of digital confidence. Hot weather and outdoor lifestyles also make sensor comfort, adhesive durability, and practical device maintenance important considerations.
• Hospitals in the UAE use diabetes care devices for inpatient glucose monitoring, insulin administration, treatment adjustment, and patient education. Their requirements include reliable measurements, compatibility with clinical protocols, staff training, and effective coordination between specialist teams. Hospitals also act as important introduction points for advanced technologies, including insulin pumps and CGM systems, by helping patients understand device operation and suitability for ongoing treatment. The availability of technical support and compatible consumables is especially important when devices are incorporated into routine clinical workflows.
• The UAE’s diagnostic centers support diabetes screening and follow-up through laboratory testing and assessments of glycemic control. Their priorities include standardized testing procedures, dependable equipment, quality assurance, and efficient patient processing. Laboratory results complement home glucose monitoring by providing information that clinicians can use alongside readings collected throughout everyday life. Diagnostic centers can strengthen their role in diabetes care through clear reporting and coordination with endocrinologists, general practitioners, and specialist clinics. For suppliers, reliable maintenance, efficient workflows, and integration with laboratory information systems are important differentiators.
• The UAE’s ambulatory surgical centers require diabetes care devices that support appropriate glucose assessment and treatment coordination around outpatient procedures. Their priorities include reliable readings, efficient clinical workflows, hygienic device handling, and clear documentation for perioperative teams. Patients may arrive using personal glucose meters, CGM sensors, insulin pens, or insulin pumps, so staff need clear procedures for reviewing existing treatment and managing devices around surgery. Manufacturers can address this segment through compact monitoring equipment, straightforward operating instructions, and staff training that supports consistent clinical practice.


Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Diabetes Care Devices Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product Type
• Blood Glucose Monitoring Systems
• Insulin Delivery Devices

By Disease Type
• Type 1 Diabetes
• Type 2 Diabetes

By End User
• Home/Self-Care
• Hospitals
• Diagnostic Centers
• Ambulatory Surgical Centers